Du är här

2014-05-16

InvestmentPitch: Zacks Small-Cap Research Initiates Coverage on Theralase Technology (TSXV:TLT) (OTCBB:TLTFF) - Video Research Alert on InvestmentPitch.com

Vancouver, BC, May 16, 2014 - Zacks Small-Cap Research has initiated coverage
on Theralase Technology (TSXV:TLT) (OTCBB:TLTFF). Analyst Anita Dushyanth
gives the company a target price of $1.00, a premium of 270% to the $0.27
price on May 6th, the day the report was issued.

InvestmentPitch.com has produced a "video research alert" about Theralase
based on this report. If this link is not enabled, please
visitwww.InvestmentPitch.comand enter "Theralase" in the search box.

Theralase designs, manufactures and markets patented, superpulsed laser
technology.

Therapeutic lasers belong to a specific class of lasers that do not cut or
destroy tissue, but instead are used to heal and have a therapeutic curative
effect on tissue. The cold laser produces an impulse of light at a specific
wavelength that minimizes reflection and scattering but maximizes absorption
of the energy at a desired depth. It can be used for healing various tissue
structures, such as muscles, tendons, ligaments, joints, connective tissues,
and bones. It can also be used for treating numerous conditions such as
muscular-skeletal conditions, nerve rehabilitation, wound healing, anti-aging
and addiction therapy.

Theralase plans to phase-out the TLC-1000 system and incentivize its customers
to upgrade to the latest technology, the TLC-2000, which is expected to be
rolled-out commercially in the fourth quarter of 2014. Theralase is actively
developing patented technology that is able to target and destroy cancers,
bacteria and viruses when light activated.

Analyst Anita Dushyanth stated, "Theralase technology is currently well
positioned in the market. The launch of
a new product, an improving economy and an aggressive sales and marketing
strategy will help boost their sales in the coming years. Theralase is backed
by a strong management team with significant knowledge and expertise along
with a strong portfolio of IP and the ability to get regulatory approvals for
therapeutic lasers
."

Cold laser therapy is usually paid for in cash at clinics, as it has limited
CPT code coverage. However, with its new patented TLC-2000 technology,
Theralase expects to secure a new CPT code for reimbursement for laser
treatments in the U.S.

On May 15th, the company announced that it has partnered with Princess
Margaret Cancer Centre, University Health Network ("UHN") to complete
preclinical research on its Photo Dynamic Compound (PDC) technology for the
destruction of cancer.

Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated, "I am
delighted that we have partnered with UHN to complete this pivotal
preclinical research. UHN is one of the top five cancer centres in the world
and provides excellent clinical and scientific support to our existing teams
to complete the preclinical work required to prepare us for a Phase 1/2a
human clinical trial for bladder cancer.
"

Roger Dumoulin-White, President and CEO stated, "2013 was a pivotal year for
Theralase, where we relocated our head office to a
better corporate location, streamlined our operations and made advancements
in both the therapeutic laser and anti-cancer divisions. 2014 will be a very
exciting year for Theralase as we increase our revenues through expansion of
our sales and marketing initiatives, launch our next generation therapeutic
laser technology and prepare to commence human clinical trials in our
anti-cancer division in early 2015
."

The company currently trades at $0.215, well below the $1.00 target price, and
with 57 million shares outstanding, the company is capitalized at $12.3
million.

For more information about Theralase, please visit the company's
websitewww.theralase.com, contact Roger Dumoulin-White, President, at
416-699-5273 ext 225, or emailrwhite@theralase.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution
for creating and hosting financial video content, and distributing it across
multiple platforms to investors and financial professionals, specializes in
producing corporate interviews and three minute videos based on news releases
and research reports. Please visit InvestmentPitch.com and browse our
extensive library of investment videos.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
604-684-5524
bmorgan@investmentpitch.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: InvestmentPitch via Globenewswire

HUG#1786689

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.